Iovance Biotherapeutics, Inc. stock faces challenges with disappointing Q1 earnings and competition. Click for why potential ...

Analysts are intrested in these 5 stocks: ( ($O) ), ( ($GTLB) ), ( ($DASH) ), ( ($IOVA) ) and ( ($SENS) ). Here is a breakdown of their recent ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Iovance Biotherapeutics’ Amtagvi study data shows 49 per cent response rate for commercialisation: San Carlos, California Thursday, July 17, 2025, 12:00 Hrs [IST] Iovance Biothe ...

Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and ...

Iovance Biotherapeutics has hired Corleen Roche as the biotechnology company's new chief financial officer, effective Aug. 6. Iovance on Tuesday said Roche, 59 years old, most recently served as ...

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.

Results from a retrospective study found that Amtagvi (lifileucel) achieved a 48.8% objective response rate in patients with ...

Iovance Biotherapeutics granted stock options to fifty new employees as part of its inducement plan, totaling 297,600 shares.

Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused ...